logo
logo

GreenLight Biosciences raises $17M financing round to accelerate large-scale manufacturing of future COVID-19 vaccines

May 12, 2020•about 5 years ago

Amount Raised

$17 Million

Boston

Description

 GreenLight Biosciences today announced it has closed an oversubscribed $17M special purpose funding round from new and existing investors to build out its scalable mRNA production capability targeting the production of billions of doses of COVID-19 vaccine. In addition to expanding its manufacturing capacity, GreenLight is developing several differentiated mRNA vaccine candidates against SARS-CoV2, the virus responsible for COVID-19. This initiative is an integral part of the company's expansion into life sciences, which include efforts to develop a large-scale vaccine platform targeting seasonal and pandemic influenza, and rapid response to emerging viruses, such as the novel coronavirus.

Company Information

Company

Green Light Biosciences, Inc.

Location

Boston, Massachusetts, United States

About

GreenLight is a bio-performance company with a unique, cell-free production platform that delivers high-performing RNA solutions to human, plant and animal challenges. GreenLight develops RNA products for plant and life science applications, and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, and plant protection. The cutting-edge, natural platform delivers higher-quality RNA at a lower cost and higher speed than was ever before possible. The GreenLight team values diversity, inclusion, and equality and promises to use collaboration to remain scientifically imaginative and passionately focused on making a difference in the world. For more information, visit https://www.greenlightbiosciences.com/.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech